Order Online! Now! Get your $50 coupon for online order.
Order Online! Now! Get your $50 coupon for online order.
Our limited edition HOLIDAYS LLAMA is here! Place any order now to recieve one!
Earn Loyalty Rewards! Up to $155 Amazon Gift Card
Time Limited Offer: Welcome Gift for New Customers !
Time Limited Offer: Welcome Gift for New Customers !
Cat. No. | Species | Product Description | Structure | Purity | Feature |
---|---|---|---|---|---|
IL2-H5210 | Human | Human IL-12 Protein, premium grade |
![]() ![]() |
![]() ![]() ![]() ![]() |
|
IL2-H8210 | Human | Biotinylated Human IL-12B&IL-12A Heterodimer Protein, His,Avitag™&Flag Tag | ![]() |
![]() ![]() |
![]() ![]() |
IL2-H4210 | Human | Human IL-12B&IL-12A Heterodimer Protein, His Tag&Flag Tag | ![]() |
![]() ![]() |
![]() ![]() ![]() ![]() |
Human IL-12 Protein, premium grade (Cat. No. IL2-H5210) stimulates secretion of IFN-γ by NK-92 human natural killer lymphoma cells. The specific activity of ActiveMax® Human IL-12 ,Tag Free (Cat. No. IL2-H5210) is > 1ⅹ10^7 IU/mg (QC tested).
Human IL-12 R beta 1, Fc Tag (Cat. No. ILB-H5255) captured on CM5 chip via Anti-human IgG Fc antibodies surface can bind Human IL-12B&IL-12A Heterodimer Protein, His Tag&Flag Tag (Cat. No. IL2-H4210) with an affinity constant of 2.06 nM as determined in a SPR assay (Biacore T200) (Routinely tested).
Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Thalidomide | NSC-66847; NSC-527179; K-17; VP-02 | Approved | Talizer, Thalidomide Celgene, Thalidomide Pharmion, Synovir, Thalomid, Thaled | Mainland China | Leprosy, Lepromatous | Fujimoto Pharmaceutical | 1982-01-01 | Osteosarcoma; Leprosy, Lepromatous; Drug Resistant Epilepsy; Primary Myelofibrosis; Neuroectodermal Tumors, Primitive; Prostatitis; Colorectal Neoplasms; Lymphoma, Mantle-Cell; Sarcoma, Ewing; Retinoblastoma; Waldenstrom Macroglobulinemia; Cholangitis, Sclerosing; HIV Wasting Syndrome; Arachnoiditis; Adenocarcinoma, Clear Cell; Prostatic Neoplasms; Pancreatitis, Chronic; Lymphoma, Follicular; Sarcoma; Xerostomia; Burning Mouth Syndrome; Neoplasm Metastasis; Mycobacterium avium-intracellulare Infection; Vascular Malformations; Amyotrophic Lateral Sclerosis; Melanoma; Carcinoma, Hepatocellular; Leukemia, Lymphocytic, Chronic, B-Cell; Myelodysplastic-Myeloproliferative Diseases; Stomatitis; Erythema Nodosum; Anemia, Sideroblastic; Uterine Neoplasms; Lymphoma, Non-Hodgkin; Glioma; Angiodysplasia; Pelvic Pain; Appendiceal Neoplasms; Lung Neoplasms; Endometrial Neoplasms; Mycobacterium Infections; Gastric Antral Vascular Ectasia; Carcinoid Tumor; Lupus Erythematosus, Discoid; Stomatitis, Aphthous; Rhabdomyosarcoma; | Details | |
Ustekinumab | CNTO-1275; C-340; AVT-04 | Approved | Janssen Global Services Llc | 喜达诺, Stelara | United States | Plaque psoriasis | Janssen Biotech Inc | 2009-09-25 | Multiple Sclerosis; Dermatitis, Atopic; Plaque psoriasis; Crohn Disease; Common Variable Immunodeficiency; Uveitis; Hidradenitis Suppurativa; Arthritis, Psoriatic; Colitis, Ulcerative; Lupus Erythematosus, Systemic; Takayasu Arteritis; Psoriasis; Liver Cirrhosis, Biliary; Arthritis, Juvenile; Spondylitis, Ankylosing; Ichthyosis; Sjogren's Syndrome; Pouchitis; Type I Leukocyte Adhesion Defect; Dermatomyositis; Inflammatory Bowel Diseases; Polymyositis; Diabetes Mellitus, Type 1 | Details |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
NSC-733972 | M-032; M032-H SV-1; NSC-733972 | Phase 2 Clinical | University Of Alabama At Birmingham | Glioblastoma; Gliosarcoma; Astrocytoma | Details |
MEDI-1191 | MEDI-1191; MEDI1191 | Phase 1 Clinical | Moderna Inc | Solid tumours; Neoplasms | Details |
ONCR-177 | ONCR-177 | Phase 1 Clinical | Oncorus Inc | Solid tumours; Liver Neoplasms; Squamous Cell Carcinoma of Head and Neck; Skin Neoplasms; Triple Negative Breast Neoplasms; Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Melanoma | Details |
INO-9012/Human papillomavirus vaccine | INO-3112; INO-9012/VGX-3100; VGX-3100/INO-9012 | Phase 2 Clinical | University Of Pennsylvania, Astrazeneca Plc, Inovio Pharmaceuticals Inc | Anus Neoplasms; Vaginal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Papillomavirus Infections; Neoplasms; Carcinoma, Transitional Cell; Vulvar Neoplasms; Oropharyngeal Neoplasms; Penile Neoplasms; Uterine Cervical Neoplasms | Details |
Apilimod mesilate | STA-5326-mesylate; LAM-002; LAM-002A; STA-5326; AIT-101 | Phase 2 Clinical | Synta Pharmaceuticals Corp, Lam | Arthritis, Rheumatoid; Coronavirus Disease 2019 (COVID-19); Common Variable Immunodeficiency; Crohn Disease; Amyotrophic Lateral Sclerosis | Details |
VG-201 | VG-201 | Phase 1 Clinical | ViroGin Biotech Ltd | Esophageal Neoplasms; Stomach Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
Ustekinumab Biosimilar (NeuClone/Serum Institute of India) | Phase 1 Clinical | Neuclone, Serum Institute Of India Ltd | Autoimmune Diseases | Details | |
EGFR IL12 CART | Phase 1 Clinical | Colorectal Neoplasms | Details | ||
ABOD-2011 | ABOD-2011 | Phase 1 Clinical | Cancer Hospital Of Chinese Academy Of Medical Sciences | Solid tumours | Details |
Ustekinumab biosimilar(DM Bio) | DA-3115; DMB-3115 | Phase 3 Clinical | Meiji Seika Pharma Co Ltd, Dong-A Pharmaceutical Co Ltd | Psoriasis | Details |
Ustekinumab biosimilar (BioFactura) | BFI-751 | Phase 1 Clinical | BioFactura Australia Pty Ltd | Psoriasis | Details |
Ustekinumab biosimilar(CSPC Pharma) | Phase 1 Clinical | Jushi Biopharmaceutical Co Ltd | Plaque psoriasis | Details | |
T3011 | MVR-T3011; T3011; MVR-T3011 IT; MVR-T3011 IV | Phase 2 Clinical | Immvira Co Ltd | Breast Neoplasms; Carcinoma, Hepatocellular; Melanoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Endometrial Neoplasms; Lymphoma; Lung Neoplasms; Colorectal Neoplasms; Solid tumours; Sarcoma; Mesothelioma; Skin Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Head and Neck Neoplasms; Ovarian Neoplasms; Liver Neoplasms | Details |
Veledimex | INXN-1001; AD-1001 | Phase 2 Clinical | Ziopharm Oncology Inc | Glioblastoma; Brain Neoplasms; Breast Neoplasms; Astrocytoma; Diffuse Intrinsic Pontine Glioma; Melanoma | Details |
Ustekinumab biosimilar(Formycon) | FYB-202 | Phase 3 Clinical | Formycon | Psoriasis | Details |
Rocakinogene sifuplasmid | INO-9012 | Phase 2 Clinical | Inovio Pharmaceuticals Inc | Urogenital Abnormalities; Precancerous Conditions; Carcinoma, Hepatocellular; Vulvar Diseases; Lung Neoplasms; Squamous Intraepithelial Lesions of the Cervix; Colorectal Neoplasms; Hepatitis C; Breast Neoplasms; Prostatic Neoplasms; Lymphoma, Mantle-Cell; Papillomavirus Infections; Ovarian Neoplasms; Neoplasms, Glandular and Epithelial; Carcinoma, Transitional Cell; Pancreatic Neoplasms; Glioblastoma; Esophageal Neoplasms; Stomach Neoplasms; Hepatitis, Chronic; Head and Neck Neoplasms; HIV Infections; Liver Neoplasms | Details |
MEDI-9253 | Phase 1 Clinical | Astrazeneca Pharmaceutical Co Ltd | Solid tumours; Neoplasms | Details | |
WTX-124 | WTX-124 | Phase 1 Clinical | Werewolf Therapeutics Inc | Solid tumours; Neoplasm Metastasis | Details |
NHS-IL-12 | M-9241; MSB-0010360 | Phase 2 Clinical | National Cancer Institute, Emd Serono Inc, Merck Serono | Vulvar Neoplasms; Sarcoma, Kaposi; Uterine Cervical Neoplasms; Urogenital Neoplasms; Penile Neoplasms; Colorectal Neoplasms; Bile Duct Neoplasms; Oropharyngeal Neoplasms; Prostatic Neoplasms; Cholangiocarcinoma; Head and Neck Neoplasms; Urinary Bladder Neoplasms; Colonic Neoplasms; Papillomavirus Infections; Pancreatic Neoplasms; Carcinoma; Rectal Neoplasms; Vaginal Neoplasms; Anus Neoplasms; Intestinal Neoplasms | Details |
Lisofylline | BL-194; CT-1501R; A-802710 | Phase 3 Clinical | Cti Biopharma Corp | Diabetes Mellitus, Type 1; Rejection of organ transplantation | Details |
INXN-2001 | Ad-RTS-hIL-12; Ad-RTS-mIL-12; INXN-2001; Ad-RTS-IL-12; INXN-2001 (Ad-RTS-IL-12); Ad-IL-12; ZIN-ATI-001 | Phase 2 Clinical | Ziopharm Oncology Inc | Glioblastoma; Breast Neoplasms; Brain Neoplasms; Astrocytoma; Diffuse Intrinsic Pontine Glioma; Melanoma | Details |
WTX-330 | WTX-330 | Phase 1 Clinical | Werewolf Therapeutics Inc | Solid tumours; Neoplasms; Lymphoma, Non-Hodgkin | Details |
TG-6050 | TG-6050 | Phase 1 Clinical | Transgene Sa | Carcinoma, Non-Small-Cell Lung | Details |
XTX-301 | XTX-301 | Phase 1 Clinical | Solid tumours; Neoplasms | Details | |
Ustekinumab biosimilar(Amgen) | ABP-654 | Phase 3 Clinical | Amgen Inc | Solid tumours; Psoriasis | Details |
DF-6002 | DF-6002 | Phase 2 Clinical | Dragonfly Therapeutics Llc | Solid tumours; Neoplasms | Details |
Ustekinumab Biosimilar (qyuns) | QX-001-S; HDM-3001; QX-001S | Phase 3 Clinical | Psoriasis; Plaque psoriasis | Details | |
Ustekinumab Biosimilar(Celltrion) | CT-P43 | Phase 3 Clinical | Celltrion Inc | Psoriasis | Details |
MVR-C5252 | C-5252; MVR-C5252 | Phase 1 Clinical | Immvira Co Ltd | Solid tumours; Ganglioglioma; Glioblastoma; Brain Neoplasms | Details |
Interleukin-12 gene therapy (OncoSec Medical) | pIL-12; DNA IL-12 | Phase 2 Clinical | Inovio Pharmaceuticals Inc | Breast Neoplasms; Mycosis Fungoides; Melanoma; Carcinoma, Hepatocellular; Lymphoma, T-Cell, Cutaneous; Lung Neoplasms; Colorectal Neoplasms; Prostatic Neoplasms; Hepatitis B; Lymphoma, Mantle-Cell; HIV Infections; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Merkel Cell; Esophageal Neoplasms; Stomach Neoplasms; Head and Neck Neoplasms; Ovarian Neoplasms | Details |
Ustekinumab biosimilar (Bio-Thera ) | BAT-2206 | Phase 3 Clinical | Bio-Thera Solutions Ltd | Autoimmune Diseases; Psoriasis; Arthritis, Psoriatic; Colitis, Ulcerative; Crohn Disease; Plaque psoriasis | Details |
Recombinant Human IL12/15-PDL1B Herpes Simplex Type I Oncolytic Virus(CNBG) | VG-161 | Phase 2 Clinical | Cnbg-Virogin Biotech (Shanghai) Ltd | Liver Neoplasms; Solid tumours; Biliary Tract Neoplasms; Esophageal Neoplasms; Pancreatic Neoplasms; Neoplasms; Cholangiocarcinoma; Carcinoma, Hepatocellular | Details |
JCXH-211 | JCXH-211 | Phase 1 Clinical | Jiachen Xihai(Hangzhou)Biotechnology Co Ltd | Solid tumours; Skin Neoplasms | Details |
This web search service is supported by Google Inc.